- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Interventions
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Glofitamab, Lenalidomide, Obinutuzumab, Positron Emission Tomography, Venetoclax
- Procedure · Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 3
- States / cities
- Duarte, California • New York, New York • Salt Lake City, Utah
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 409–432
of 703
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- Isatuximab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2030
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
- Interventions
- bortezomib, lenalidomide, dexamethasone
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 275
- States / cities
- Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Dexamethasone, Ibrutinib, Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study, Quality-of-Life Assessment
- Drug · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
- Interventions
- Azacitidine, Lenalidomide
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Lymphoma, Non-Hodgkin's
- Interventions
- lenalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 20
- States / cities
- Muscle Shoals, Alabama • Scottsdale, Arizona • Fountain Valley, California + 17 more
- Conditions
- Multiple Myeloma
- Interventions
- CC-5013
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2006
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma
- Interventions
- Venetoclax, Lenalidomide, Rituximab, Rituximab and Hyaluronidase Human
- Drug · Biological
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Lymphoid Leukemia, Small Lymphocytic Lymphoma, Lymphoma, Non-Hodgkin
- Interventions
- Bendamustine, Rituximab, Lenalidomide
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Solid Tumors
- Interventions
- Dasatinib, Erlotinib, Lapatinib, Lenalidomide, Sorafenib, Sunitinib, Valproic Acid
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Not listed
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Interventions
- Lenalidomide
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Light Chain Deposition Disease, Smoldering Multiple Myeloma
- Interventions
- Clinical Observation, Lenalidomide, Quality-of-Life Assessment
- Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2027
- U.S. locations
- 601
- States / cities
- Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 390 more
- Conditions
- Multiple Myeloma
- Interventions
- Pomalidomide, Dexamethasone, Daratumumab
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2025
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Greenbrae, California • Los Angeles, California + 28 more
- Conditions
- Myeloma
- Interventions
- Lenalidomide, Bortezomib, Siltuximab, Dexamethasone, Questionnaires
- Drug · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, autologous hematopoietic cell transplantation
- Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Basking Ridge, New Jersey • Middletown, New Jersey + 8 more
- Conditions
- Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory B-Cell Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Lenalidomide
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Aurora, Colorado • Columbus, Ohio
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide and low-dose dexamethasone, Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles, Melphalan, Prednisone and Thalidomide
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,623 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2016
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 25 more
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma
- Interventions
- Ulocuplumab, Lenalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Complex Regional Pain Syndrome, Type I
- Interventions
- lenalidomide, Placebo
- Drug
- Lead sponsor
- Celgene Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 184 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 27
- States / cities
- Peoria, Arizona • La Jolla, California • Loma Linda, California + 23 more
- Conditions
- Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
- Interventions
- Dexamethasone, Lenalidomide, Pomalidomide
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Lymphoma, Follicular
- Interventions
- Atezolizumab (MPDL3280A) [TECENTRIQ], Lenalidomide, Obinutuzumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Miami, Florida • Louisville, Kentucky + 2 more
- Conditions
- Chronic Lymphocytic Leukemia, Fatigue, Fever, Hypogammaglobulinemia, Lymphadenopathy, Lymphocytosis, Night Sweats, Paraproteinemia, Small Lymphocytic Lymphoma, Thrombocytopenia
- Interventions
- Lenalidomide, Ofatumumab
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Plasma Cell Myeloma, Transplant-Related Carcinoma
- Interventions
- Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide
- Drug · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Prostate Cancer
- Interventions
- sargramostim, lenalidomide, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- Robert Dreicer MD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio